Despite promising clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is facing substantial resistance from pharmacy benefit managers. These companies are typically erecting barriers to access, such as high expense criteria and PA that hinder user access. Market suggest that such coverage hur… Read More